Drugs / PXVX0047
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03160339 | May → Nov 2017 | adenoviridae infectious disease | Emergent BioSolutions | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PXVX0047 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03160339 ↗ |
| Modality | Vaccine | “PXVX0047 is an investigational vaccine developed for active immunization” PMID 37376480 ↗ Jun 2023 |
| Route | Oral | “PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration.” NCT03160339 ↗ |